Share repurchase
Filed with HKEX · Stock code 2595 · · 2 pages · English
Summary by 6ix AI
The company acknowledged a non-compliance incident where a portion of the shares were repurchased above the price limit set by the Listing Rules due to an inadvertent error. To address this issue, the company has implemented remedial measures including revised operational procedures and training sessions on regulatory compliance for its management and directors.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/share-repurchase-4
Genfleet Therapeutics (Shanghai), Inc. on 6ix
Earlier from Genfleet Therapeutics (Shanghai)
- Next Day Disclosure Return
- Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 October 2026
- VOLUNTARY ANNOUNCEMENT Multiple Innovative Combination Therapies of Oral Pan RAS Inhibitor GFH276 Recently Granted with Clinical Trial Approvals for First-line and Late-line Clinical Studies Addressing Major Tumor Indications in China or Abroad
- VOLUNTARY ANNOUNCEMENT Initial Clinical Readout of GFH276 (an Oral Molecular-glue Pan RAS Inhibitor) Presented as Late-breaking Abstract (LBA) at 2026 ESMO Annual Meeting, Demonstrating Promising Clinical Potential and Favorable Safety in Pretreated RAS-mutant Solid Tumors
Follow Genfleet Therapeutics (Shanghai) into a list and get an email when it puts out news.
Follow Genfleet Therapeutics (Shanghai)